GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » Other Net Income (Loss)

China National Accord Medicines (SZSE:000028) Other Net Income (Loss) : ¥-0 Mil (TTM As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is China National Accord Medicines Other Net Income (Loss)?

China National Accord Medicines's Other Net Income (Loss) for the three months ended in Mar. 2024 was ¥-0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-0 Mil.

China National Accord Medicines's quarterly Other Net Income (Loss) declined from Sep. 2023 (¥0 Mil) to Dec. 2023 (¥-0 Mil) but then increased from Dec. 2023 (¥-0 Mil) to Mar. 2024 (¥-0 Mil).

China National Accord Medicines's annual Other Net Income (Loss) declined from Dec. 2021 (¥0 Mil) to Dec. 2022 (¥-0 Mil) and declined from Dec. 2022 (¥-0 Mil) to Dec. 2023 (¥-0 Mil).


China National Accord Medicines Other Net Income (Loss) Historical Data

The historical data trend for China National Accord Medicines's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Other Net Income (Loss) Chart

China National Accord Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

China National Accord Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

China National Accord Medicines Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Accord Medicines Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
Executives
Su Wei Wei Independent director
Chen Chang Bing Secretary Dong
Peng Juan Director
Fu Ming Zhong Director

China National Accord Medicines (SZSE:000028) Headlines

No Headlines